This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by King, N. M.
Right arrow Articles by Schiffer, C. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by King, N. M.
Right arrow Articles by Schiffer, C. A.

 Previous Article  |  Next Article 

Journal of Virology, November 2004, p. 12012-12021, Vol. 78, No. 21
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.21.12012-12021.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor

Nancy M. King,1 Moses Prabu-Jeyabalan,1 Ellen A. Nalivaika,1 Piet Wigerinck,2 Marie-Pierre de Béthune,2 and Celia A. Schiffer1*

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts,1 Tibotec, Mechelen, Belgium2

Received 5 March 2004/ Accepted 8 June 2004

TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely potent against both wild-type (wt) and multidrug-resistant (MDR) viruses in vitro as well as in vivo. Although chemically similar to amprenavir (APV), the potency of TMC114 is substantially greater. To examine the basis for this potency, we solved crystal structures of TMC114 complexed with wt HIV-1 protease and TMC114 and APV complexed with an MDR (L63P, V82T, and I84V) protease variant. In addition, we determined the corresponding binding thermodynamics by isothermal titration calorimetry. TMC114 binds approximately 2 orders of magnitude more tightly to the wt enzyme (Kd = 4.5 x 10–12 M) than APV (Kd = 3.9 x 10–10 M). Our X-ray data (resolution ranging from 2.2 to 1.2 Å) reveal strong interactions between the bis-tetrahydrofuranyl urethane moiety of TMC114 and main-chain atoms of D29 and D30. These interactions appear largely responsible for TMC114's very favorable binding enthalpy to the wt protease (–12.1 kcal/mol). However, TMC114 binding to the MDR HIV-1 protease is reduced by a factor of 13.3, whereas the APV binding constant is reduced only by a factor of 5.1. However, even with the reduction in binding affinity to the MDR HIV protease, TMC114 still binds with an affinity that is more than 1.5 orders of magnitude tighter than the first-generation inhibitors. Both APV and TMC114 fit predominantly within the substrate envelope, a property that may be associated with decreased susceptibility to drug-resistant mutations relative to that of first-generation inhibitors. Overall, TMC114's potency against MDR viruses is likely a combination of its extremely high affinity and close fit within the substrate envelope.

* Corresponding author. Mailing address: Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605-2324. Phone: (508) 856-8008. Fax: (508) 856-6464. E-mail: Celia.Schiffer{at}umassmed.edu.

Journal of Virology, November 2004, p. 12012-12021, Vol. 78, No. 21
0022-538X/04/$08.00+0     DOI: 10.1128/JVI.78.21.12012-12021.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Saskova, K. G., Kozisek, M., Rezacova, P., Brynda, J., Yashina, T., Kagan, R. M., Konvalinka, J. (2009). Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir. J. Virol. 83: 8810-8818 [Abstract] [Full Text]  
  • Vermeir, M., Lachau-Durand, S., Mannens, G., Cuyckens, F., van Hoof, B., Raoof, A. (2009). Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects. Drug Metab. Dispos. 37: 809-820 [Abstract] [Full Text]  
  • Descamps, D., Lambert-Niclot, S., Marcelin, A.-G., Peytavin, G., Roquebert, B., Katlama, C., Yeni, P., Felices, M., Calvez, V., Brun-Vezinet, F. (2009). Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 63: 585-592 [Abstract] [Full Text]  
  • Mosebi, S., Morris, L., Dirr, H. W., Sayed, Y. (2008). Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study. J. Virol. 82: 11476-11479 [Abstract] [Full Text]  
  • Sayer, J. M., Liu, F., Ishima, R., Weber, I. T., Louis, J. M. (2008). Effect of the Active Site D25N Mutation on the Structure, Stability, and Ligand Binding of the Mature HIV-1 Protease. J. Biol. Chem. 283: 13459-13470 [Abstract] [Full Text]  
  • Lambert-Niclot, S., Flandre, P., Canestri, A., Peytavin, G., Blanc, C., Agher, R., Soulie, C., Wirden, M., Katlama, C., Calvez, V., Marcelin, A.-G. (2008). Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir. Antimicrob. Agents Chemother. 52: 491-496 [Abstract] [Full Text]  
  • Dierynck, I., De Wit, M., Gustin, E., Keuleers, I., Vandersmissen, J., Hallenberger, S., Hertogs, K. (2007). Binding Kinetics of Darunavir to Human Immunodeficiency Virus Type 1 Protease Explain the Potent Antiviral Activity and High Genetic Barrier. J. Virol. 81: 13845-13851 [Abstract] [Full Text]  
  • Poveda, E., de Mendoza, C., Martin-Carbonero, L., Corral, A., Briz, V., Gonzalez-Lahoz, J., Soriano, V. (2007). Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 60: 885-888 [Abstract] [Full Text]  
  • Colebunders, R., Vlieghe, E., Maniewski, U., Schepens, T., Hollanders, E., Gheuens, E., De Roo, A. (2007). Lessons Learned From 2 Patients With Multidrug-Resistant HIV-1 Infection Successfully Treated With a Darunavir-Containing Antiretroviral Treatment Regimen. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 203-205 [Abstract]  
  • Nalam, M. N. L., Peeters, A., Jonckers, T. H. M., Dierynck, I., Schiffer, C. A. (2007). Crystal Structure of Lysine Sulfonamide Inhibitor Reveals the Displacement of the Conserved Flap Water Molecule in Human Immunodeficiency Virus Type 1 Protease. J. Virol. 81: 9512-9518 [Abstract] [Full Text]  
  • Busse, K. H. S., Penzak, S. R. (2007). Darunavir: A second-generation protease inhibitor. Am J Health Syst Pharm 64: 1593-1602 [Abstract] [Full Text]  
  • Pauwels, F., Mostmans, W., Quirynen, L. M. M., van der Helm, L., Boutton, C. W., Rueff, A.-S., Cleiren, E., Raboisson, P., Surleraux, D., Nyanguile, O., Simmen, K. A. (2007). Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors. J. Virol. 81: 6909-6919 [Abstract] [Full Text]  
  • Muzammil, S., Armstrong, A. A., Kang, L. W., Jakalian, A., Bonneau, P. R., Schmelmer, V., Amzel, L. M., Freire, E. (2007). Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations. J. Virol. 81: 5144-5154 [Abstract] [Full Text]  
  • Sekar, V., Kestens, D., Spinosa-Guzman, S., De Pauw, M., De Paepe, E., Vangeneugden, T., Lefebvre, E., Hoetelmans, R. M. W. (2007). The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)/Ritonavir in HIV-Negative Healthy Volunteers. J Clin Pharmacol 47: 479-484 [Abstract] [Full Text]  
  • Foulkes, J. E., Prabu-Jeyabalan, M., Cooper, D., Henderson, G. J., Harris, J., Swanstrom, R., Schiffer, C. A. (2006). Role of Invariant Thr80 in Human Immunodeficiency Virus Type 1 Protease Structure, Function, and Viral Infectivity. J. Virol. 80: 6906-6916 [Abstract] [Full Text]  
  • Prabu-Jeyabalan, M., King, N. M., Nalivaika, E. A., Heilek-Snyder, G., Cammack, N., Schiffer, C. A. (2006). Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease.. Antimicrob. Agents Chemother. 50: 1518-1521 [Abstract] [Full Text]  
  • Prabu-Jeyabalan, M., Nalivaika, E. A., Romano, K., Schiffer, C. A. (2006). Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.. J. Virol. 80: 3607-3616 [Abstract] [Full Text]  
  • De Meyer, S., Azijn, H., Surleraux, D., Jochmans, D., Tahri, A., Pauwels, R., Wigerinck, P., de Bethune, M.-P. (2005). TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates. Antimicrob. Agents Chemother. 49: 2314-2321 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»